Preclinical tools and models in Hurler syndrome (MPS I-H)
Preclinical systems play a central role in understanding severe MPS I (Hurler syndrome) and in advancing therapeutic approaches such as systemic gene delivery, refined transplantation strategies and next-generation enzyme replacement.
This page outlines the core in vivo and in vitro platforms used in MPS I-H research and explains how they connect to biomarkers, efficacy endpoints and translational decision-making.
Animal model • Cell culture • Assays mapped across organs
Why preclinical models matter in MPS I-H
Due to disease rarity and clinical variability, translational programmes in MPS I-H rely heavily on well-designed preclinical evidence.
- Reproduce IDUA deficiency and glycosaminoglycan accumulation at cellular and organ levels.
- Enable evaluation of vectors, dosing strategies and delivery routes before human studies.
- Link biochemical correction to structural, functional and survival outcomes.
- Reduce development risk by defining safety, biodistribution and off-target effects early.
Animal models used in Hurler syndrome research
Mouse models with targeted disruption of the Idua gene remain the most widely used systems, offering reproducible multi-organ pathology and progressive disease features.
Typical characteristics
- Severely reduced or absent IDUA enzymatic activity.
- Marked glycosaminoglycan accumulation in tissues and biofluids.
- Progressive visceral, skeletal and cardiac involvement.
- Central nervous system changes and reduced lifespan in severe variants.
Primary applications
- Dose selection and route comparison for systemic gene delivery.
- Assessment of enzyme replacement, transplant-based or adjunctive therapies.
- Longitudinal tracking of biomarkers, imaging and functional endpoints.
Cellular models and assay platforms
In vitro and ex vivo systems complement animal studies by supporting mechanistic insight and early screening.
- Animal-derived primary cells: fibroblasts, hepatocytes and macrophages for transduction and storage assays.
- Patient-derived cells: where available, used to explore genotype-specific biology and therapeutic response.
- Engineered cell systems: IDUA disruption or over-expression for controlled studies.
- Assay development: enzyme activity, substrate quantification and early toxicity profiling.
Assays integrated with models
Enzyme activity
IDUA measurements in plasma, cells and tissue homogenates.
GAG profiling
Total and species-specific sulphated GAGs in biofluids and organs.
Histology & imaging
Storage burden, tissue architecture and advanced imaging where available.
Functional outcomes
Survival, motor performance and behavioural assessments.
Experimental design, controls and timing
- Careful selection of disease stage and intervention window.
- Appropriate wild-type and disease control groups.
- Clear dosing rationale and delivery strategy.
- Defined early and late assessment time points.
- Use of randomisation and blinded outcome assessment where feasible.
Tools for safety and biodistribution
- Vector copy number and integration analyses across tissues.
- Comprehensive organ biodistribution panels.
- Clinical pathology and targeted histopathology.
- Assessment of humoral and cellular immune responses.
Digital, computational and analytical tools
- Statistical pipelines for longitudinal and survival data.
- Image analysis for histology, bone and organ structure.
- Integrated datasets combining biochemical and functional outcomes.
- Exploratory translational and dose-scaling models.
Practical tips for building a preclinical toolbox
- Focus on a limited number of well-characterised core models.
- Define a consistent primary assay panel across studies.
- Add exploratory endpoints in a structured, hypothesis-driven way.
- Maintain detailed protocols suitable for regulatory submission.
- Align with emerging core outcome frameworks where possible.
Preclinical tools and models at a glance
- Animal models remain the backbone of translational MPS I-H research.
- Cellular systems add mechanistic and screening capability.
- Robust assays are essential for efficacy interpretation.
- Safety and biodistribution data underpin advanced therapies.
Animal models & study design
Model selection and experimental planning
Efficacy outcomes
Behavioural, biochemical and tissue endpoints
Safety & biodistribution
Risk and tissue distribution assessment
Biomarkers & outcomes
Linking molecular correction to benefit
Vector design & mechanism
Platform considerations for delivery
Translational roadmap
From preclinical data to first-in-human studies